Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Human Study
Adults with type 2 diabetes and painful neuropathy
4 mg subcutaneously once daily for 28 days
This phase 2 schedule was followed by another 28 days of observation and is not a routine-use protocol.
View sourceEvidence summary
An erythropoietin-derived tissue-protective peptide studied in small phase 2 neuropathy trials. Schedules are disease-specific and remain investigational.
Protocol basis
The page reports the repeated 28-day subcutaneous research design used in small neuropathy studies, with the population and monitoring context attached.
What remains uncertain
Larger confirmatory trials, long-term safety, approved indications and equivalence to commercial research vials remain unresolved.
Warnings and contraindications
ARA-290 remains investigational and is not a general neuropathy treatment.
The cited daily schedule was tested for 28 days in small monitored studies.
Results from specific neuropathy populations do not establish broader use.